Drugs / TQB2928
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06585059 | Sep 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06297642 | May → Jul 2024 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT06438783 | Feb 2024 → Jun 2025 | osteosarcoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT06008405 | Sep 2023 → May 2025 | acute myeloid leukemia, myelodysplastic syndrome | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05192512 | Jan 2022 → Jan 2024 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04854681 | Aug 2021 → Jul 2022 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2928 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06297642 ↗ |
| Known as | TQB2928 injection | “TQB2928 injection is a CD47 Blocker.” NCT05192512 ↗ |
| Action | Inhibit | “TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages.” NCT04854681 ↗ |
| Modality | Monoclonal antibody | “TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.” NCT06008405 ↗ |
| Route | Intravenous | “weekly intravenous (IV) infusions” NCT05192512 ↗ |
| Target | CD47 | “TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages.” NCT04854681 ↗ |